CVS Health (NYSE:CVS) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Posted by Stacy Sanders on May 16th, 2026

CVS Health (NYSE:CVS – Get Free Report) had its price objective boosted by equities research analysts at Morgan Stanley from $93.00 to $106.00 in a report issued on Thursday, MarketBeat reports. The firm currently has an “overweight” rating on the pharmacy operator’s stock. Morgan Stanley’s price target points to a potential upside of 10.48% from the stock’s previous close.

Several other research firms also recently commented on CVS. Barclays raised their target price on CVS Health from $93.00 to $101.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Sanford C. Bernstein raised their price target on CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a report on Tuesday. DA Davidson increased their target price on CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Piper Sandler lowered their target price on CVS Health from $101.00 to $99.00 and set an “overweight” rating for the company in a research note on Tuesday, March 31st. Finally, HSBC raised their target price on CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a research note on Tuesday, May 5th. Twenty-two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.08.

Read Our Latest Research Report on CVS

CVS Health Price Performance

CVS Health stock opened at $95.95 on Thursday. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The company has a market capitalization of $122.42 billion, a PE ratio of 42.27, a price-to-earnings-growth ratio of 0.95 and a beta of 0.60. CVS Health has a one year low of $58.50 and a one year high of $98.43. The business has a 50 day simple moving average of $78.71 and a 200 day simple moving average of $78.59.

CVS Health (NYSE:CVS – Get Free Report) last posted its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.CVS Health’s revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the company earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, sell-side analysts forecast that CVS Health will post 7.44 EPS for the current fiscal year.

Insider Activity at CVS Health

In other news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On CVS Health

Several hedge funds and other institutional investors have recently made changes to their positions in the company. National Pension Service grew its stake in shares of CVS Health by 3.1% during the third quarter. National Pension Service now owns 3,999,622 shares of the pharmacy operator’s stock worth $301,532,000 after purchasing an additional 119,189 shares during the period. Kingsview Wealth Management LLC grew its stake in shares of CVS Health by 316.2% during the third quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock worth $7,873,000 after purchasing an additional 79,340 shares during the period. AE Wealth Management LLC grew its stake in shares of CVS Health by 6.2% during the third quarter. AE Wealth Management LLC now owns 257,204 shares of the pharmacy operator’s stock worth $19,391,000 after purchasing an additional 14,983 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of CVS Health by 11.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 225,116 shares of the pharmacy operator’s stock worth $16,971,000 after purchasing an additional 22,653 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its stake in shares of CVS Health by 186.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 396,368 shares of the pharmacy operator’s stock worth $30,568,000 after purchasing an additional 258,050 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

Positive Sentiment: Morgan Stanley raised its price target on CVS Health and kept an overweight rating, signaling confidence in further upside after the company’s stronger-than-expected quarterly results. Morgan Stanley Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price
Positive Sentiment: Argus also lifted its outlook for CVS Health, adding to the wave of analyst support that may be helping shares move higher. Argus Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price
Positive Sentiment: CVS reported solid Q1 2026 earnings recently, beating estimates on both revenue and adjusted EPS, which continues to drive investor optimism about execution and valuation. Here is Why CVS Health (CVS) is One of the Cheap Stocks to Buy For the Next 10 Years
Positive Sentiment: CVS and WGU launched an online pre-pharmacy degree program to help build a stronger pharmacist pipeline, a move that could support long-term staffing and service growth. CVS Health® and WGU launch online pre-pharmacy degree program for future pharmacists nationwide
Neutral Sentiment: CVS advanced its portfolio reset by selling Omnicare after bankruptcy court approval, which simplifies the business and removes an underperforming unit, but also confirms ongoing restructuring. CVS Refocuses On Core Health Platform With Omnicare Sale And Drone Rollout
Neutral Sentiment: CVS also highlighted community and brand-building initiatives in Rhode Island, including its economic impact report and expanded WIC acceptance, which are positive for reputation but less likely to move the stock on their own. CVS Health’s Annual Impact in Rhode Island

CVS Health Company Profile

(Get Free Report)

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.